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Boston, MA, USA; 4University of Minnesota, Minneapolis, MN, USAA B S T R A C TObjectives: To assess the impact of simulating temporal changes in
health-care practice patterns when calibrating longitudinal models to
cross-sectional data. Methods: AMarkovmodel of cervical cancer was
alibrated to recent age-specific US data on the prevalence of cervical
bnormalities, cervical cancer incidence, and related mortality. The
mpact of failing to account for temporal changes in screening prac-
ices was assessed by comparing results from 1) a conventional cali-
ration that incorrectly assumed that all women had been exposed to
urrent screening practices in the past and 2) an historically accurate
alibration that reflected the fact that US women 65 years of age and
lder had not received currently available screening practices at
ounger ages. Results: The parameter set derived from conventional
calibration produced a cervical cancer incidence rate of 13.4 per 100,000
amongwomen aged 65 years and older, which is equal to the target end
point. However, when this parameter set was used in the model to
bot R
al So
doi:10.1016/j.jval.2011.01.002simulate the effects of historically correct screening, cervical incidence
and related mortality in the 65 years and older age group were overes-
timated by 18% and 47%, respectively. Finally, when the parameter set
was correctly calibrated by assuming historical changes in screening in
the calibration process, excellent calibration to both incidence and
mortality was obtained. Conclusions: Calibrating longitudinal models
to cross-sectional data without accounting for temporal changes in
clinical practice may result in a parameter set that is not as optimized
as it appears and may lead to bias in evaluating the effectiveness of
interventions.
Keywords: cervical cancer, cross-sectional data,model calibration, tem-
poral changes.
Copyright © 2011, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Twelve thousand women in the United States were diagnosed
with cervical cancer in 2006, and approximately 4000 women died
of the disease during that year [1]. The natural history of cervical
cancer begins with infection by human papillomavirus (HPV),
which leads to formationof cervical cell abnormalities called cervical
intraepithelial neoplasia (CIN),whichmayultimatelyprogress to cer-
vical cancer [2–5]. These CIN, or precursor cervical lesions, can be
further categorized as CIN1 (mild abnormality), CIN2 (moderate to
marked abnormality), andCIN3 (severe abnormality). To informclin-
ical and policy choices regarding HPV vaccination and cervical
screening,wedevelopedaMarkovcohortmodelofHPV infectionand
its progression to CIN lesions and cervical cancer for the US setting.
Input parameters for diseasemodels are generally informed by
data from the published literature, registries, and databases. How-
ever, data sourcesmay vary andmay not provide all the necessary
input required for a disease model, for example, rates of progres-
sion between cervical disease states are not readily available for
modeling purposes. In such cases, researchers must use alterna-
tive data estimation techniques to work around this obstacle. One
technique is calibration, which involves adjusting input transition
probabilities until model-estimated outcomes (such as incidence
* Address correspondence to: Vivek Pawar, PhD, i3 Innovus, 10 Ca
E-mail: vivek.pawar@i3innovus.com.
1098-3015/$36.00 – see front matter Copyright © 2011, Internation
Published by Elsevier Inc.of disease and associated mortality) match corresponding epide-
miologic data from available sources [6].
Calibration is used frequently in mathematical models of can-
cer, but the nomenclature varies. Stout et al. [6] conducted a re-
view of 154 cancer-screening models and determined that 85%
may have used calibration during model estimation, even though
many studies did not explicitly use the term. These authors sug-
gested that descriptions of calibration methodologies should be
standardized and expanded on in futuremodeling endeavors, par-
ticularly as the use of mathematical models in evaluating cancer
policy decisions in the United States becomes more widespread.
Because it is not possible to observe progression rates between
cervical disease states in clinical practice and comprehensive data
on cervical cancer incidence and survival are readily available [7],
calibration is often performed for models of HPV and cervical dis-
ease [8–10].
One of the most critical components of the calibration process
is the selection of disease end points that can serve as target val-
ues of model outputs. Reliable epidemiological data to use as
benchmarks for model outputs are necessary to ensure predictive
validity and credibility of model results. End points are tradition-
ally drawn from cross-sectional data on disease outcomes, such as
population-based disease prevalence, incidence, and mortality at
a point in time. If disease outcomes are dependent on model in-
oad, Suite 304, Medford, MA 02155, USA.
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
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other clinical prevention strategies), there could be challenges
when calibrating a longitudinal model. A calibration process that
fails to account for these temporal changes may lead to bias in
inferring transition probabilities between disease states.
The potential impact of the bias in ourmodel of cervical cancer
is made clear when one considers that Papanicolaou (Pap) smear
testing of cervical lesions did not gain widespread acceptance in
the United States until the early 1950s [11]. Therefore, a woman
born before 1938 (age 65 years and older at the time of our analysis)
did not have access to screening when she first reached the eligible
screening age of 15 years. Similarly, a woman born in 1928 (age 75
years at the time of our analysis) did not receive her first Pap smear
until 25 years of age or later. Additionally, there was a period of up-
take as Pap smear use increased, so annual screening rates were
lower for women currently 65 years of age and older in their earlier
years than they are today [12]. Current cross-sectional data on cervi-
cal cancer incidenceandmortality [7] intrinsically reflect the fact that
older women did not experience current screening practices when
they were younger. Not accounting for this phenomenon in the cal-
ibration process may lead to errors in estimating rates of cervical
disease progression by assuming that screening had occurred more
frequently in the past than it actually did. These errorsmay, in turn,
lead to errors in predicting the health consequences of interventions
such as HPV vaccination and cervical screening on cervical out-
comes.
The objectives of this study were, therefore, to 1) assess the
consequences of failing to account for temporal changes in cervi-
cal cancer screening practices when calibrating a longitudinal
model of HPV infection and cervical disease and 2) establish the
importance of accounting for temporal changes in input in future
cancer model calibration efforts.
Methods
Model overview
We developed aMarkov (state-transition) model capable of simulat-
ing the natural history of HPV infection and subsequent cervical dis-
ease [13]. Themodel is composed of a set of mutually exclusive, col-
lectively exhaustive health states (Fig. 1); the natural history of
cervical disease is modeled as a series of transitions between these
states that occur at 6-month intervals, referred to as Markov cycles.
Probabilities governing these transitions are conditional on age and
the type of HPV infection.
The health states are classified according to the stage of cervi-
cal disease: normal (no HPV infection); HPV infection with no le-
sion; CIN1; CIN2; CIN3; invasive cervical cancer (stage 1, stage 2,
stage 3, or stage 4); and death from cervical cancer or other causes.
The four stages of cancer are subdivided according to the status of
Fig. 1 – Simplified structure of the human papillomavirus (H
history of HPV infection and cervical disease using 6-month
transitions are dependent on HPV type and age. Transitions
cervical intraepithelial neoplasia.diagnosis (detected or undetected). The health states (except nor-mal) are further stratified according to seven types or categories of
HPV infections: HPV types 16, 18, 31, 45, 52, other high-risk (in-
cludes HPV types 33, 35, 39, 51, 56, 58, 59, 66, and 68), and low-risk.
Itwas assumed that an infection candevelop inwomenwithnoHPV
infection and those with CIN1–3 can progress, regress, or stay the
same; onlywomenwith CIN3 can progress to stage 1 cervical cancer.
Consistent with the natural history of HPV, womenwith cancer can,
ineachcycle, progress to thenext stageof cancerbutno regression to
the previous health state is allowed. Movement from undetected
cancer to detected cancer is defined by the stage-dependent proba-
bility of the development of symptoms or cancer being detected
through screening. Transitions to death are determined by cancer
stage–specific survival rates, as reported in theSurveillanceEpidemi-
ology and End Results Data (SEER) registry [7] and competing all-
cause mortality risks [14].
Calibration end points and model parameters
A total of 35 calibration end points were evaluated, including five
disease end points (prevalence of CIN1, CIN2, and CIN3, and cervical
cancer incidence and mortality) within each of 5 age groups plus
overall age-adjusted values for each end point (Table 1). These end
pointswere chosennot only because reliable datawere readily avail-
able to estimate them, but also because they are the primary clinical
outcomes of cervical disease. CIN end pointswere derived frompub-
lished literature [15], whereas cervical cancer incidence andmortal-
ity endpointswerederived fromtheSEERdatabase. Specifically, can-
cer incidence and mortality end points were obtained by querying
the SEER database using the Fast Stats tool [7], which provides quick
access to key cancer statistics for major cancer sites. Seventy-nine
natural history input parameters (transition probabilities) that were
considered to be themost influential on cervical end points, but that
were not estimated precisely by published data sources, were in-
cluded in the model calibration (Table 2). Age group–specific transi-
tions betweendisease stateswere calibrated forHPV type 16. To sim-
plify the calibration, transitionprobabilities forHPV type 18, for other
high-risk types, and for low-risk typesweremodeled as type-specific
multiples of the corresponding transition probabilities for HPV type
16. These type-specific multipliers were also calibrated, such that
hundreds of transition probabilities were effectively varied and cali-
brated.
Assessing the goodness-of-fit of calibration results
Goodness of fit measures the accuracy of the calibrated input in
replicating the target end points [6]. It can be measured using a
mathematical function (objective function); we used the weighted
mean percentage deviation from target end points as our objective
function to be optimized (minimized). The mean percentage devi-
ation for each end point was calculated by dividing the absolute
value of the difference between the model-based estimate of the
atural history model. The model simulates the natural
sition probabilities. The probabilities governing these
eath can occur from any health state in the model. CIN =PV) n
tran
to dend point and the data-based target value of the end point by the
w702 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 7 0 0 – 7 0 4target value. We then weighted each end point to calculate the
weighted mean deviation using the following equation:
Weighted Mean Percentage Deviation
i1
n
wi
|predi  obsi|
obsi
,
here n  number of end points, predi model-based estimate of
the ith end point, obsi data-based target value of the i
th end point,
and wi  weight assigned to the i
th end point.
Weights were assigned to each end point based on the reliabil-
ity of available data and perceived importance for the analysis.
Thus, a greater weight was assigned to aggregated CIN end points
relative to age-specific CIN end points (1.0 vs. 0.2). Additionally, all
cervical cancer incidence andmortality end points (individual and
aggregated) were assigned weights six and three times greater,
respectively, than the corresponding CIN end points. This weight-
ing approach permits the modeler to place greater importance on
end points, such as mortality, that are either more precisely esti-
mated from the epidemiological data or that are regarded as influ-
ential in determining the value of interventions or both.
Parameter search algorithms
The objective of a mathematical search algorithm is to identify a
parameter set within a continuous parameter space that opti-
mizes an objective function.We chose the Nelder-Mead algorithm
[16] as our search method because of its computational efficiency
and simplicity compared to other nonlinear optimizationmethods
(e.g., simulated annealing and genetic algorithm) [17,18].
Table 1 – Cervical cancer-related calibration target end poin
Calibration end points in a
screened population
15–29 30–
Prevalence of CIN1 37.2 10.9
Prevalence of CIN2 16.3 5.0
Prevalence of CIN3 14.4 8.2
Incidence of cervical cancer 2.6 12.6
Incidence of cervical cancer mortality 0.23 2.0
Prevalence estimates are per 1000 population for the years 1995 to 2001
CIN, cervical intraepithelial neoplasia.
* Population weighted average.
Table 2 – Seventy-nine natural history input parameters in
Transition probabilities No. of calib
paramet
From health state To health state
No HPV infection No HPV infection 12
No HPV infection HPV infection 6
HPV infection CIN1 7
HPV infection CIN2 7
CIN1 CIN2 9
CIN1 CIN3 3
CIN2 CIN3 10
CIN3 Cervical cancer 11
Stage I cervical cancer Death 4
Stage II cervical cancer Death 4
Stage III cervical cancer Death 3
Stage IV cervical cancer Death 3
Total calibrated parameters 79CIN, cervical intraepithelial neoplasia; HPV, human papillomavirus.Adjusting for temporal changes in model calibration
Because our model is intended to simulate HPV vaccination and
cervical cancer screening intervention strategies prospectively for
a simulated cohort of 12-year-old females in the United States, we
originally assumed that current cervical cancer screening prac-
tices were in place for the lifetime of the cohort.We refer to this as
the single-stage model (SSM). This assumption implies that the
oldest cohort involved in the calibration had been screened ac-
cording to current practices throughout their lives. An input pa-
rameter set that is calibrated using the SSMwill produce transition
probabilities that reflect, incorrectly, this assumption that screen-
ing in the past was performed according to current practices. Such
a calibration is referred to as a single-stage calibration (SSC).
To reflect changes in screening practices over time, we divided
the model population into two groups: 1) those younger than 65
years of age in 2003 (i.e., born after 1938) who experienced current
cervical screening practices for their lifetimes and 2) those aged 65
years of age and older in 2003 who did not have the full benefit of
screening at younger ages. We refer to this approach as the two-
stage model (TSM). Despite changes in screening practices in the
past, we assumed that the natural history of cervical cancer pro-
gression had not changed; thus, a single set of transition probabil-
ities applies to both stages. We used the two-stage model in sim-
ulations of historical cohorts to estimate the single parameter set
that best fit the age-group specific target end points; we refer to
this process as a two-stage calibration (TSC). For these two-stage
simulations, weassumedno screeninguntil 1953, afterwhich yearly
ge groups in years Weighted
average*
40–49 50–64 65
4.8 2.4 0.8 12.9
1.8 0.8 0.5 5.6
3.5 2.1 1.5 6.5
15.8 14.7 13.4 11.2
3.83 5.27 7.14 3.46
dence estimates are per 100,000 population for the years 2002 to 2003.
ed in the calibration.
d Additional details
Calibrated parameters included age group–specific transition
probabilities associated with remaining in the no HPV
infection health state. Transition probabilities to HPV
type–specific infection were determined indirectly using
calibrated HPV type–specific multipliers
Calibrated parameters included age group–specific transition
probabilities associated with HPV type 16. Other age
group–specific transition probabilities, specifically those
associated with HPV type 18, other high-risk types, and
low-risk types, were determined indirectly using
calibrated HPV type–specific multipliers
Transitions to death were calibrated by age group and not by
HPV typets.
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703V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 7 0 0 – 7 0 4screening rates were interpolated linearly from 1953 through 1966
based on screening data available for 1961 and 1963. Cervical screen-
ing rates increased from 10 per 100 females in 1961 to 26 per 100
females in 1966 as the use of the Pap test became more widespread
[12]. The rate reported for 1966 is consistent with current screening
practices, so the uptake in the use of the Pap test was assumed to be
complete by that year, with screening ratesmatching current guide-
lines [12,19] (Fig. 2).
Testing the impact of temporal changes on model calibration
Nelder-Mead optimization [16] was used in both the SSC and TSC
o produce best-fitting parameter sets. To measure the bias cre-
ted by failing to incorporate temporal changes in cervical screen-
ng, we ran the parameter set from the SSC in both the SSM and
SM and calculated the differences between the end points. These
esults were then compared to the results of running the param-
ter set from the TSC in the TSM.
Results
Model-generated cervical cancer incidence and mortality rates by
type of calibration in women 65 years of age and older are pre-
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Fig. 2 – Annual screening coverage by age.
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Fig. 3 – Differences in model-generated cervical cancer mort
years of age and older. Note: Targets are age adjusted from
database. SSC/SSM, results of a single-stage calibration (SSC
TSM, results of an SSC derived from an SSM, run in a two-st
derived from a two-stage model (TSM), run in a TSM.sented in Figure 3. When an SSC is performed using the SSM (life-
ong screening according to current practices for all women), the
est-fitting parameter set generates a cervical cancer incidence rate
f 13.4per 100,000 forwomen65years of ageandolder.Although this
ate appears to be consistent with SEER target end points, running
he sameparameter set in a TSM that incorporates historical screen-
ng patterns results in an 18% overestimation (15.8 per 100,000
omen) of cervical cancer incidence. For cervical cancer mortality,
he SSC/SSM approach generates a mortality rate of 5.7 per 100,000
20% less than the target value of 7.1). The rate increases to 10.5 per
00,000 (47%more than the target), when the parameter set from the
SC is used in the TSM. Running the parameter set from the TSC in
he TSM produces the best estimates for cervical cancer incidence
nd mortality in the 65 years and older age group: 13.4 per 100,000
target: 13.4) and 7.3 per 100,000 (target: 7.1) respectively.
Discussion
The primary objective of our study was to assess the effects of
calibrating a longitudinalmodel to cross-sectional datawhile both
accounting for and not accounting for temporal changes in cervi-
cal screening practices. Primary end points were cervical cancer
incidence and mortality rates derived from cross-sectional age-
specific SEER data. The model projects lifetime disease outcomes
prospectively for a cohort of 12-year-old US females who can be
expected to experience current cervical screening rates during
their lifetime. Using current age-specific screening rates as model
input, while targeting cervical cancer incidence and mortality
rates for women currently 65 years of age and older, creates a
temporal disconnect.
The temporal disconnect can be explained by observation of
the dynamic between two important aspects of the model: 1)
screening and 2) disease progression rates and their impact on the
cervical outcomes, mainly, incident cases and mortality. Increas-
ing screening will lead to fewer cervical outcomes, whereas in-
creasing the disease progression rates leads to more cervical out-
comes.
Women 65 years of age and older experienced lower screening
rates during their 20s and 30s [12], precisely the period in their lives
when cervical abnormalities were most likely to develop and possi-
bly later progress to cervical cancer. By incorrectly assuming that
13.43
15.81
13.42
SSC / SSM SSC / TSM TSC / TSM
lacivreC  Cancer Incidence
Target: 13.41
+18%
and incidence rates by calibration technique for women 65
urveillance, Epidemiology and End Results (SEER)
ived from a single-stage model (SSM), run in an SSM. SSC/
model. TSC/TSM, results of a two-stage calibration (TSC)32
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704 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 7 0 0 – 7 0 4these older womenwere screened in their younger at-risk years, the
SSC increased disease progression rates to match disease end point
targets that reflect the fact that these women had not actually been
screened.
As a consequence, the inflated disease progression parameters
derived from the SSC led to overestimation of cervical disease and
mortality when they were entered into a two-stage model that
simulated actual screening patterns over the lifetimes of these
women. Our model likely would have predicted cervical cancer
incidence and mortality rates 18% and 47%, respectively, higher
than would be expected after the 12-year-old cohort reached age
65 years. Finding a set of transitions that account for screening
rates for women younger than 65 years of age as well as those 65
years and older facilitated an accurate calibration to correspond-
ing epidemiological end points.
Our results indicate that it could be important to consider tem-
poral changes in input when calibrating longitudinal models to
cross-sectional data, particularly for diseases in which progres-
sion is slow and early detection is beneficial. Overestimation can
have a substantial impact on policy decisions guided by model
results. For example, overestimating cervical cancer mortality
could lead to recommendations for cervical screening above opti-
mal levels, which in turn would result in excessive resource utili-
zation and costs. If possible, adjustments should be made to re-
flect the experience of the population from which cross-sectional
epidemiological targets are derived when calibrating a longitudi-
nal model of future outcomes.
It is important to note that the goal of calibration,with orwithout
adjustments for temporal changes in input, is to produce a single
parameter set that achieves a good fit for the entire population. Al-
though we used a TSM that accounted for historical changes in
screening patterns to calibrate model inputs, our final model is an
SSM that uses current screening rates.
One of the limitations of this study is that the impact of how the
advent of new treatments influenced current cervical cancer inci-
dence and mortality data was not considered. It is likely that ad-
vances in cervical cancer treatment such as radiation therapy and
chemotherapy will be reflected by fewer cervical cancer–related
deaths in our target epidemiological data. This aspect was not con-
sidered in this analysis due to absence of readily available data on
uptake and use of new treatments.
Conclusion
Our findings apply broadly to chronic diseases for which recent
breakthroughs in testing or changes in screening practices or rec-
ommendations could have altered current morbidity and mortal-
ity. Examples include breast cancer screening mammography,
flexible sigmoidoscopy and colonoscopy for colorectal cancer, im-
plementation of blood supply screening for hepatitis C virus, and
hepatitis B surface antigen testing to detect the presence of hepa-
titis B infection. The objective of this article is to highlight theimportance of considering temporal factors can affect calibration
targets and adjusting for these factors in the calibration process in
future models of cervical cancer and other chronic disease condi-
tions.
Source of financial support: GlaxoSmithKline, Philadelphia, PA,
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